This delayed release formulation was proved to be one of blockbuster product in the recent time.
This salt form was developed into a delayed release capsule formulation and was approved by the FDA.
The optimized formulations have a high drug loading (>25%) and nanoparticle yield (>93%), small particle size with a narrow distribution, and exhibit delayed release.
Salofalk® displayed both delayed release and extended release characteristics.
These include drugs delivered through controlled release, delayed release, or targeted release systems.
Usually, delayed-release formulations are a way for big drug companies to keep generic firms at bay.
Still, the company has a good record of keeping drugs under patent protection by altering them with extended- and delayed-release formulations and the like.
Due to the easy preparation and regeneration, the proposed sensor opens new opportunity for fast, simple and sensitive analysis of drug and its metabolite in human serum samples as well as direct quantification of mesalazine in delayed-release formulations.
Due to a significant decrease in the peak-trough fluctuation of plasma valproic acid levels, in comparison with the twice-daily dosing of conventional delayed-release formulations, concentration-dependent side effects would be prevented, also avoiding inefficacy of the treatment.
The newly marketed MDR capsule and discontinued tablet (Asacol®) formulations have a pH-dependent release mechanism designed to delay release until the formulation reaches the distal gastrointestinal (GI) tract (pH~6.5), thus, increasing the level of exposure to the colon in patients with ulcerative colitis.
